Paraganglion neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Paraganglion neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors. https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ Thu, 30 Apr 2026 13:08:57 +0000 https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ This study focuses on individuals with various types of cancer, including Renal Cell Carcinoma, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Esophageal Squamous Cell Carcinoma, and Pancreatic Neuroendocrine Tumor. It also includes people with Advanced Pheochromocytoma/Paraganglioma, Advanced Gastrointestinal Stromal Tumor, and certain types of Colorectal Cancer, Endometrial Cancer, or Solid Tumors that have specific genetic changes called HIF-2α related genetic alterations. Additionally, the research involves patients with von Hippel-Lindau Disease-Associated Tumors, which are tumors caused by a specific genetic condition. The purpose of the study is to evaluate the long-term effectiveness and safety of certain treatments.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

]]> Study on the Effectiveness of Lutetium (177Lu) Edotreotide for Patients with Neuroendocrine Tumors and Other SSTR-Positive Tumors https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lutetium-177lu-edotreotide-for-patients-with-neuroendocrine-tumors-and-other-sstr-positive-tumors/ Wed, 29 Apr 2026 15:03:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lutetium-177lu-edotreotide-for-patients-with-neuroendocrine-tumors-and-other-sstr-positive-tumors/ This clinical trial is focused on studying the effects of a treatment called 177Lu-DOTATOC on certain types of tumors. The tumors being studied include Neuroendocrine Tumors and other tumors that are positive for a specific receptor known as SSTR. This includes conditions like Pheochromocytomas and Paragangliomas, as well as Bronchopulmonary Neuroendocrine Tumors. The treatment involves using a solution that is given through an infusion into the veins.

The purpose of the study is to evaluate how effective the 177Lu-DOTATOC treatment is for patients with these types of tumors. The study will follow patients over a period of time to see how their tumors respond to the treatment. Some patients will receive the actual treatment, while others may receive a placebo. The study will also monitor the safety of the treatment by checking for any side effects that occur during and after the treatment period.

Participants in the study will undergo regular assessments to track the progress of their disease and any changes in their quality of life. These assessments will include standard questionnaires and medical imaging tests like MRI or CT scans. The study aims to provide valuable information on the potential benefits and risks of using 177Lu-DOTATOC for treating these specific types of tumors.

]]> Study on Using Exenatide PET/CT Imaging for Detecting Paragangliomas in Patients https://clinicaltrials.eu/trial/study-on-using-exenatide-pet-ct-imaging-for-detecting-paragangliomas-in-patients/ Wed, 29 Apr 2026 14:58:56 +0000 https://clinicaltrials.eu/trial/study-on-using-exenatide-pet-ct-imaging-for-detecting-paragangliomas-in-patients/ This clinical trial is focused on studying a type of tumor called paragangliomas. These are rare tumors that can develop in nerve tissue. The study is testing a new imaging technique called Exendin PET/CT to see if it can effectively detect these tumors. The imaging technique uses a special substance called 68Ga-exendin-4, which is injected into the body to help highlight the tumors during the scan.

The purpose of the study is to determine if this new imaging method can successfully identify paragangliomas. Participants in the study will undergo the Exendin PET/CT scan, which involves a combination of positron emission tomography (PET) and computed tomography (CT) to create detailed images of the body. The study will also compare the results of this new method with other standard imaging techniques to see how well it performs.

Throughout the study, researchers will look at how well the Exendin PET/CT scan detects paragangliomas and determine the best time to perform the scan for optimal results. They will also explore how the imaging results relate to certain characteristics of the tumors, such as their genetic makeup. The study aims to provide valuable information that could improve the way paragangliomas are diagnosed in the future.

]]> Study on the Safety of Lutetium (177Lu) Oxodotreotide, L-Lysine Hydrochloride, and L-Arginine Hydrochloride in Adolescents with Neuroendocrine Tumors and PPGLs https://clinicaltrials.eu/trial/study-on-the-safety-of-lutetium-177lu-oxodotreotide-l-lysine-hydrochloride-and-l-arginine-hydrochloride-in-adolescents-with-neuroendocrine-tumors-and-ppgls/ Wed, 29 Apr 2026 14:27:31 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-lutetium-177lu-oxodotreotide-l-lysine-hydrochloride-and-l-arginine-hydrochloride-in-adolescents-with-neuroendocrine-tumors-and-ppgls/ This clinical trial is focused on studying certain types of tumors, specifically gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pheochromocytoma, and paragangliomas. These are rare types of tumors that can occur in the digestive system and other parts of the body. The study is testing a treatment called Lutathera, which is a solution given through an infusion into the veins. Lutathera contains a substance called lutetium (177Lu) oxodotreotide, which is designed to target and treat these tumors.

The purpose of the study is to evaluate how safe Lutathera is for use in adolescents and to understand how the body absorbs the radiation from this treatment. Another medication used in the study is called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride. These are amino acids that help protect the kidneys during the treatment. The study will involve monitoring the participants over a period of time to see how their bodies respond to the treatment and to check for any side effects.

Participants in the study will receive the treatment over a period of up to 36 months. During this time, doctors will closely monitor the participants’ health and the effects of the treatment. The study aims to gather information on the safety and effectiveness of Lutathera in treating these specific types of tumors in adolescents. This information will help in understanding how well the treatment works and its potential side effects.

]]>